Position in EYPT
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$15,015,000
+$1,480,500 QoQ
Shares Held
1,050,000
0.0% QoQ
Ownership
1.22%
of shares outstanding
% of Portfolio
5.32%
of 13F equity value
Holder Rank
#21
of 188 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EYPT Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 20265AM Venture Management, LLC holds $282,021,658 across 16 Biotechnology names. EYPT ranks #10 (5.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MPLT |
MapLight Therapeutics, Inc.
|
950,011 | $34,048,394 | |
| 2 | TYRA |
Tyra Biosciences, Inc.
|
1,029,298 | $32,875,778 | |
| 3 | TRDA |
Entrada Therapeutics, Inc.
|
4,056,379 | $29,854,949 | |
| 4 | PHVS |
Pharvaris N.V.
|
797,600 | $27,581,008 | |
| 5 | CAMP |
Camp4 Therapeutics Corp
|
5,869,091 | $25,647,927 | |
| 6 | ARTV |
Artiva Biotherapeutics, Inc.
|
2,353,304 | $22,827,048 | |
| 7 | TECX |
Tectonic Therapeutic, Inc.
|
606,660 | $20,856,970 | |
| 8 | ZNTL |
Zentalis Pharmaceuticals, Inc.
|
3,947,913 | $19,147,378 |
All Filings in EYPT
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $15,015,000 | 1,050,000 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $13,534,500 | 1,050,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $19,183,500 | 1,050,000 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $14,952,000 | 1,050,000 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $9,880,500 | 1,050,000 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $5,691,000 | 1,050,000 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $7,822,500 | 1,050,000 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $8,389,500 | 1,050,000 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $435,000 | 50,000 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||